相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- ASTRO released its first standalone clinical practice guideline on radiation therapy for bladder cancer, published in Practical Radiation Oncology and developed with ASCO, EAU and ESTRO. - The guideline strongly recommends trimodal therapy as an alternative to radical cystectomy for select patients with cT2-4aN0M0 muscle-invasive bladder cancer. - Recommendations also cover adjuvant radiation after cystectomy, dose-fractionation schedules, and palliative or consolidative radiation in metastatic disease. - The task force flagged persistent disparities, including lower receipt of curative-intent treatment among Black patients and reduced access in rural communities.
- Emmaus Life Sciences has signed an exclusive option agreement with Cedars-Sinai to continue evaluating L-glutamine oral powder combined with chemotherapy in pancreatic ductal adenocarcinoma. - The agreement follows GlutaPanc Phase 1 results, recently published in Nature Cancer, showing tumor shrinkage in 94% of 16 patients, including two complete responses. - The option grants Emmaus an exclusive 18- to 24-month window to exercise the option and sign a license agreement, building on a 2021 collaboration. - Cedars-Sinai's Beverly Grove campus is expected to be a site for planned Phase 3 trials enrolling at least several hundred patients, though efficacy and safety remain unestablished.
- Nanox reported Q1 2026 revenue of $4.3 million, up from $2.8 million in Q1 2025, driven by teleradiology services and consolidation of Nanox Health IT. - A Nanox.ARC system is now in commercial use at RadNet, the largest U.S. outpatient imaging center operator, with discussions underway for expanded deployment. - The company withdrew its 2026 revenue target, citing longer-than-expected timelines between commercial agreements, system deployment, and revenue recognition. - Cash and equivalents stood at $44.2 million as of March 31, 2026, with management flagging substantial doubt about the company's ability to continue as a going concern without additional financing.
- The PARTNER 2 trial's 10-year follow-up shows transcatheter aortic valve replacement (TAVR) with SAPIEN 3 yields comparable survival and durability to surgical aortic valve replacement (SAVR) in intermediate-risk patients. - At 10 years, rates of death or disabling stroke were similar between TAVR and surgery (TAVR 55.0% vs SAVR 55.8%, p=0.76), with no significant difference in bioprosthetic valve failure. - TAVR was associated with lower rates of new-onset atrial fibrillation and major bleeding, while surgery showed fewer paravalvular leaks and reinterventions. - The findings support TAVR as a durable, less-invasive alternative to surgery for intermediate-risk aortic stenosis patients with life expectancy beyond 5 years.
- The five-year cancer survival rate in the U.S. reached 70% in 2025, with over 19 million survivors nationwide and projections of 26 million by 2040. - Advanced practice providers (APPs) are increasingly leading survivorship clinics, offering scalable, multidisciplinary care that addresses long-term physical, cognitive, and psychosocial needs. - Leading cancer centers including MD Anderson, Stanford, and Cedars-Sinai are embedding APPs, nurse navigators, and digital health tools to ensure continuity beyond active treatment. - Research efforts are expanding to address underserved groups, including older adults, rural survivors, and those with advanced or metastatic disease, through virtual coaching and structured exercise programs.
- The Boao Lecheng International Medical Tourism Pilot Zone has reduced the average approval timeline for overseas innovative medical products to just 1.6 days, down from years previously. - As China's only "medical special zone," Lecheng has introduced over 500 innovative medicines and devices, benefiting nearly 280,000 patients to date. - A new expedited pre-approval policy prioritizes innovative drugs and devices targeting rare diseases and serious, life-threatening conditions. - The zone hosted nearly 10,000 overseas medical trips in 2025 and has partnerships with more than 180 pharmaceutical companies across 20 countries.
- Cedars-Sinai received up to $5.05 million from ARPA-H to develop KronosRx, an AI-driven platform that predicts drug toxicity before clinical trials begin. - The platform combines human-derived organoids and organ-on-chip systems with AI models trained on millions of patient data points to create "patient avatars." - More than 30% of clinical trials currently fail due to adverse drug reactions not detected in preclinical testing, driving up development costs and delaying treatments. - KronosRx aims to reduce reliance on animal testing while improving drug safety predictions across diverse patient populations with varying ages and health conditions.
- Immorta Bio published preclinical data in the Journal of Translational Medicine showing SenoVax™ significantly reduced tumors in mouse models of lung, brain, pancreatic, and breast cancers. - The novel immunotherapy targets senescent cells to reprogram the tumor microenvironment, converting immunologically "cold" tumors to "hot" by boosting CD8+ T-cell infiltration. - The company has filed IND #30745 with the FDA for a first-in-human trial in advanced lung cancer and is completing GMP manufacturing requirements. - SenoVax™ demonstrated statistically significant tumor growth inhibition and prolonged survival in both orthotopic and syngeneic models as monotherapy and in combination treatments.
- Cedars-Sinai researchers have developed TY1, the first "exomer" drug that repairs DNA damage and regenerates tissue without using stem cells, representing a breakthrough after two decades of research. - The synthetic RNA molecule enhances TREX1 gene activity to boost immune cells that clear damaged DNA, minimizing scar tissue formation after heart attacks and improving recovery outcomes. - TY1 shows therapeutic potential beyond cardiac applications, demonstrating efficacy in autoimmune diseases where the body attacks healthy tissue. - The drug is now advancing to clinical trials, potentially establishing a new class of therapeutics for treating tissue damage from heart attacks, inflammatory diseases, and other conditions.
- The PARTNER 3 trial demonstrates that transcatheter aortic valve replacement (TAVR) provides similar clinical outcomes to surgery at 7 years in low-risk patients with severe aortic stenosis. - Bioprosthetic valve failure rates were comparable between treatments, with 6.9% for TAVR and 7.3% for surgery, addressing durability concerns. - The study found no significant difference in the composite endpoint of death, stroke, or rehospitalization, with rates of 34.6% for TAVR versus 37.2% for surgery. - These findings support TAVR as a viable long-term treatment option for low-risk patients, though valve thrombosis rates remained higher with TAVR at 2.8% versus 0.5% for surgery.
